An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors

Background. Alirocumab and evolocumab, as protein convertase subtilisin kexin type 9 (PCSK9) inhibitors, have been reported to reduce cardiovascular risk. This meta-analysis is aimed at updating the safety data of PCSK9 inhibitors. Methods. We assessed the relative risk for all treatment-related adv...

Full description

Bibliographic Details
Published in:	Cardiovascular Therapeutics
Main Authors:	Hye Duck Choi, Ji Hae Kim
Format:	Article
Language:	English
Published:	Wiley 2023-01-01
Online Access:	http://dx.doi.org/10.1155/2023/7362551

Similar Items

Early effects of PCSK9 inhibitors: evolocumab versus alirocumab
by: Su-Hyun Bae, et al.
Published: (2025-03-01)

Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis
by: Guoguang Xiao, et al.
Published: (2024-10-01)

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
by: Joshua Choi, et al.
Published: (2017-07-01)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
by: Maram H. Abduljabbar
Published: (2024-11-01)

Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis
by: Lin Zhang, et al.
Published: (2025-02-01)

A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries
by: Hui-Hui Liu, et al.
Published: (2026-05-01)

Quantitative assessment of baseline imbalances in evolocumab and alirocumab trials: a meta-epidemiological study
by: F. H. van Bruggen, et al.
Published: (2024-06-01)

Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk
by: Renata Rajtar-Salwa, et al.
Published: (2024-07-01)

Efficacy and safety of inclisiran, evolocumab and alirocumab in patients with high, very high and extreme cardiovascular risk
by: N. G. Lozhkina, et al.
Published: (2025-04-01)

Indirect comparison of the efficacy and safety of alirocumab and evolocumab on major cardiovascular events: a systematic review and network meta-analysis
by: Leyu Xu, et al.
Published: (2025-06-01)

Protective effect of alirocumab, a PCSK9 inhibitor, on the sciatic nerve of rats with diabetic peripheral neuropathy
by: Na Cui, et al.
Published: (2024-03-01)

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
by: Xiang Zhang, et al.
Published: (2020-05-01)

Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials
by: Seyyed Majid Eslami, et al.
Published: (2017-04-01)

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat
by: Hong-Fei Wang, et al.
Published: (2022-12-01)

Effects of Alirocumab and Evolocumab on Cardiovascular Mortality and LDL-C: Stratified According to the Baseline LDL-C Levels
by: Hui Ma, et al.
Published: (2025-04-01)

Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab vs Evolocumab
by: Pierre Sabouret, et al.
Published: (2026-04-01)

Retrospective Observational Analysis in a Cohort Patients in Treatment with Alirocumab and Evolocumab: Focus on C-LDL Values
by: Salvatore Coppolino
Published: (2025-04-01)

Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study
by: Maciej Banach, et al.
Published: (2023-06-01)

Naturally Occurring PCSK9 Inhibitors: An Updated Review
by: Jungmoo Huh, et al.
Published: (2025-09-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
by: Elisa Waldmann, et al.
Published: (2022-01-01)

Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk
by: Alessia Silla, et al.
Published: (2023-02-01)

Evolocumab prevents atrial fibrillation in rheumatoid arthritis rats through restraint of PCSK9 induced atrial remodeling
by: Xuejie Han, et al.
Published: (2024-07-01)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
by: Michael D. Shapiro, et al.
Published: (2019-02-01)

PCSK9 inhibitors
by: Baris Gencer, et al.
Published: (2015-04-01)

Therapeutic Low-Density Lipoprotein Cholesterol-Lowering in a Patient With Familial Hyperlipidemia Refractory to PCSK9 Monoclonal Antibody (Evolocumab)
by: Stephanie Skove, et al.
Published: (2023-05-01)

Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
by: Aarti Ramanathan, et al.
Published: (2016-01-01)

The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of hospitals: an interrupted time series analysis
by: Wan Tang, et al.
Published: (2025-09-01)

PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis
by: Ding-Qiang Chen, et al.
Published: (2024-07-01)

Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
by: Thorsten M. Leucker, et al.
Published: (2020-07-01)

Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study)
by: Jie Xu, et al.
Published: (2024-07-01)

Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials
by: Ajay K Shukla, et al.
Published: (2019-01-01)

Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease
by: Haixia Tang, et al.
Published: (2025-08-01)

PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01)

Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program
by: T. O. Bessonova, et al.
Published: (2023-04-01)

Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report
by: Massimiliano Allevi, et al.
Published: (2023-06-01)

Efficacy and safety of the use of alirocumab in real clinical practice
by: Viktoria A. Korneva, et al.
Published: (2023-01-01)

Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)Plain-Language Summary
by: Cara East, et al.
Published: (2022-07-01)

PCSK9 INHIBITORS IN PERIPHERAL ARTERY DISEASE: REVIEW OF EFFICACY, SAFETY, AND OUTCOMES
by: Moiud Mohyeldin
Published: (2024-09-01)

Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease
by: Borja Quiroga, et al.
Published: (2020-09-01)